Pharmacodynamic assessment of platelet reactivity after a loading dose of prasugrel or clopidogrel in patients with ST-segment elevation myocardial infarction

Circulation Journal

Volumn 80, Issue 12, 2016, Pages 2520-2527

  Ichikawa, Shinya ^a   Tsukahara, Kengo ^a   Minamimoto, Yugo ^a   Kimura, Yuichiro ^a   Matsuzawa, Yasushi ^a   Maejima, Nobuhiko ^a   Iwahashi, Noriaki ^a   Hibi, Kiyoshi ^a   Kosuge, Masami ^a   Ebina, Toshiaki ^a   Kimura, Kazuo ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Clopidogrel; Percutaneous coronary intervention; Platelet reactivity; Prasugrel; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; CYTOCHROME P450; GLUCOSE; HEMOGLOBIN; HEPARIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NECROSIS; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOCYTE COUNT; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PRASUGREL HYDROCHLORIDE; ST ELEVATION MYOCARDIAL INFARCTION; TICLOPIDINE;

EID: 84997343240     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0513     Document Type: Article

References (35)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494 – 502.
2. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411 – 2420.
3. Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010; 74: 679 – 685.
4. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657 – 666.
5. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312 – 2317.
6. Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: What have we learnt from recent trials? Eur Heart J 2016; 37: 344 – 352.
7. Nakamura M, Yamagishi M, Ueno T, Hara K, Ishiwata S, Itoh T, et al. Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry. Cardiovasc Interv Ther 2013; 28: 162 – 169.
8. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS 2nd, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects. Platelets 2009; 20: 316 – 327.
9. Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49: 777 – 798.
10. Zhu B, Effron MB, Kulkarni MP, Li YG, Jakubowski JA, Miller DL, et al. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. J Cardiovasc Pharmacol 2011; 57: 317 – 324.
11. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001 – 2015.
12. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684 – 1692.
13. Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study. Int J Cardiol 2015; 182: 541 – 548.
14. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011; 4: 585 – 594.
15. Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. J Cardiol 2013; 62: 158 – 164.
16. Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, et al. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. J Cardiol 2016; 68: 29 – 36.
17. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354 – 362.
18. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008; 371: 1353 – 1363.
19. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045 – 1057.
20. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797 – 804.
21. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601 – 1606.
22. Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: The ETAMI trial (early thieno-pyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv 2015; 8: 147 – 154.
23. Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: The CRUSH study. J Am Coll Cardiol 2016; 67: 1994 – 2004.
24. Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013; 369: 901 – 909.
25. Wessler JD, Genereux P, Mehran R, Ayele GM, Brener SJ, McEntegart M, et al. Which intraprocedural thrombotic events impact clinical outcomes after percutaneous coronary intervention in acute coronary syndromes?: A pooled analysis of the HORIZONS-AMI and ACUITY trials. JACC Cardiovasc Interv 2016; 9: 331 – 337.
26. Genereux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: Insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63: 619 – 629.
27. Alexopoulos D, Xanthopoulou I, Goudevenos J. Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2014; 113: 2064 – 2069.
28. Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015; 8: 1457 – 1467.
29. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015; 8: e001593, doi:10.1161/ CIRCINTERVENTIONS.114.001593.
30. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 2013; 382: 1981 – 1992.
31. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, et al. Prasugrel versus tirofiban bolus with or without short post- bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268 – 277.
32. Rafique AM, Nayyar P, Wang TY, Mehran R, Baber U, Berger PB, et al. Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A network meta-analysis. JACC Cardiovasc Interv 2016; 9: 1036 – 1046.
33. Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J 2014; 167: 909 – 914.
34. Alexopoulos D, Makris G, Xanthopoulou I, Patsilinakos S, Deftereos S, Gkizas V, et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Pharmacodynamic study. Circ Cardiovasc Interv 2014; 7: 233 – 239.
35. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: The MOJITO study. J Am Coll Cardiol 2015; 65: 511 – 512.